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Abstract: The idiopathic inflammatory myopathies are a heterogeneous group of diseases that 
include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and other less 
common myopathies. These are clinically and histopathologically distinct diseases with many 
shared clinical features. IBM, the most commonly acquired inflammatory muscle disease occurs 
in individuals aged over 50 years, and is characterized by slowly progressive muscle weakness and 
atrophy affecting proximal and distal muscle groups, often asymmetrically. Unlike DM and PM, 
IBM is typically refractory to immunotherapy. Although corticosteroids have not been tested in 
randomized controlled trials, the general consensus is that they are not efficacious. There is some 
suggestion that intravenous immunoglobulin slows disease progression, but its long-term effective-
ness is unclear. The evidence for other immunosuppressive therapies has been derived mainly from 
case reports and open studies and the results are discouraging. Only a few clinical trials have been 
conducted on IBM, making it difficult to provide clear recommendations for treatment. Moreover, 
IBM is a slowly progressive disease so assessment of treatment efficacy is problematic due to the 
longer-duration trials needed to determine treatment effects. Newer therapies may be promising, but 
further investigation to document efficacy would be expensive given the aforementioned need for 
longer trials. In this review, various treatments that have been employed in IBM will be discussed 
even though none of the interventions has sufficient evidence to support its routine use.
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Introduction
Inclusion body myositis (IBM) is the most common acquired muscle disease in adults 
aged over 50 years, with a 3:1 male preponderance and a prevalence estimated at 
4 to 9/100,0001 with an incidence rate of 0.79 per 100,000.2 IBM is more common 
in Caucasians and considered to be rare among Asians and African-Americans.3 It is 
a relentlessly, albeit slowly, progressive disorder that leads to markedly impaired 
mobility, dysphagia or even death. Most patients require an assistive mobility device 
within 10 years of onset.4,5 The cause of the disease is unknown, but immunologic 
and degenerative features play a role in disease pathogenesis. The immunopathologic 
hallmarks certainly resemble those seen in polymyositis (PM), making it difficult 
for clinicians to distinguish IBM from PM, particularly early in the disease course. 
Refractoriness to treatment is usually seen in these patients.
Clinical features
Patients with IBM present with an insidious onset of slowly progressive weakness and 
the condition is more frequently seen in males (3:1 male to female ratio). There is a 
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wide range of ages at presentation from 35 years to 90 years, 
but most of the patients present after the age of 50 years, 
with a mean age of onset of around 60 years. IBM is often 
misdiagnosed as PM due to similar initial presentation with 
symmetrical proximal weakness of lower extremity with 
creatine kinase (CK) elevation. However, IBM has some 
unique clinical features that may help in distinguishing 
the two: often asymmetric; distal muscle involvement; and 
neuropathic features with early weakness and atrophy of the 
quadriceps, the forearm flexor muscles (ie, wrist and finger 
flexors), and the ankle dorsiflexors.
At least 60% of patients develop dysphagia, which can be 
severe as well as the presenting symptom.6,7 The dysphagia 
is not necessarily due to a true pharyngeal myopathy as seen 
with PM or DM, and patients often complain of a “blocking 
sensation” with swallowing. Imaging or manometry reveals 
cricopharyngeal achalasia, amenable to cricopharyngeal 
dilatation or myotomy. CK levels are modestly elevated 
(,10 × upper limit of normal) especially early in the course, 
unlike polymyositis (PM). The typical needle electromyo-
graphy (EMG) finding in IBM is mixed myopathic (small 
short-amplitude motor unit action potential) and neuropathic 
(prolonged large-amplitude motor unit action potential) 
changes: however there are often only myopathic patterns 
with increased insertional activity, fibrillations, and poly-
phasic potentials, similar to PM. Nerve conduction studies 
are usually normal. Magnetic resonance imaging (MRI) is an 
emerging tool to help in the diagnosis of IBM and may help 
to differentiate it from PM. MRI abnormalities in IBM tend 
to be fibrofatty changes and atrophy localized to quadriceps, 
gastrocnemius, and anterior forearm muscle groups and show 
more asymmetry than in PM, although there is significant 
overlap in the MRI findings of the two disorders.8
A recent study showed that involvement of the medial 
compartment of the gastrocnemius, combined with relative 
sparing of the rectus femoris or involvement of the flexor 
digitorum profundus can be indicative of IBM.8 The insidious 
onset and slow evolution of the disease process accounts, in 
part, for the misdiagnosis and delay in diagnosis, sometimes 
up to 6 to 8 years after the onset of symptoms.9 Patients are 
often unable to date the onset of their muscle weakness, 
unlike those with PM or dermatomyositis (DM).
The diagnosis of IBM is often confirmed by degenera-
tive and inflammatory features on muscle biopsy showing 
endomysial inflammation of nonnecrotic muscle fibers with 
one or more characteristic basophilic rimmed vacuoles,10,11 
but several biopsies may be necessary before the classic 
features are found. Eosinophilic cytoplasmic inclusions 
may be found adjacent to the basophilic-rimmed vacuoles 
on light microscopy, which are more specific for IBM but 
not sensitive. Within the rimmed vacuoles, amyloid deposi-
tion is evident on Congo red staining using polarized light 
or fluorescence techniques.12 Electron microscopy typically 
demonstrates 15 nm to 21 nm cytoplasmic and intranuclear 
tubulofilaments within muscle fibers, which generally is 
considered diagnostic.10,11 Some researchers have questioned 
the reliability of pathologic criteria for the diagnosis of IBM 
proposed by Griggs et al, since some patients with clini-
cal features of IBM lack the canonical pathologic features 
(inflammatory myopathy with mononuclear cell invasion 
of nonnecrotic muscle fiber, vacuolated muscle fibers, and 
either intracellular amyloid deposits or 15–18 nm tubulofila-
ments by EMG13) of the disease even after repeated muscle 
biopsies.14–16 The endomysial inflammation is characterized 
by the presence of T cell-mediated and MHC-I-restricted 
cytotoxicity; clonal expansion of autoinvasive CD8+ T cells 
and B cells and upregulation of cytokines, chemokines, and 
costimulatory molecules. The degenerative features consist 
of vacuolization in myofibers not invaded by T cells and 
intracellular deposits of amyloid and related proteins. In spite 
of the antigen-driven T cell response and immunopatho-
logic features, immunotherapies have not been successful, 
suggesting to some authors that this argues against an auto-
immune basis and points towards a more neurodegenerative 
pathophysiology.17–19
An important management consideration is how to treat 
patients with typical IBM features who lack the characteristic 
rimmed vacuoles and congophilic myofiber deposits, thus 
making it difficult to differentiate between PM and IBM.14 
Many such patients are treated as PM but do not meet the 
2004 proposed criteria for PM,20 although they satisfy the 
research criteria for possible13 and probable IBM.21 In a recent 
retrospective study of the treatment responsiveness of 16 such 
“PM/IBM” patients, only 29% patients had stabilization and 
none had sustained improvement with immunosuppressive 
therapy; by comparison, all 24 patients with patterns of 
weakness typical of PM showed improvement or stabilization 
with immunotherapy.22 Similar results were reported 
previously.14–16 These studies support the importance of the 
pattern of weakness as the distinguishing feature predicting 
treatment response in patients with an inflammatory 
myopathy. The lack of response to immunosuppressive 
agents in patients with an IBM pattern of weakness, but 
no concordant histopathologic features, suggests that these 
patients have IBM rather than PM. Whether these patients 
tend to “stabilize” with immunotherapy more than patients 
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with both typical pathologic and clinical features of IBM is 
an important question that remains to be studied.
Although inclusion body myositis is a slowly progressive 
disabling disease with 37% of patients requiring a wheel 
chair and another 38% requiring a cane after 10–15 years of 
diagnosis, large observational studies suggest that it is not 
associated with increased mortality and immunosuppressive 
treatments do not change the natural course of the disease.23,24 
The mean time from the first symptoms to using a walking 
stick and wheelchair is 11 and 16 years, respectively.24
Treatment
General considerations
Since all the common immunotherapeutic agents are gener-
ally ineffective, IBM has no established treatment paradigm 
or standard-of-care approach. Whether therapies help to 
slow the progression of the disease is also unclear, despite 
a handful of studies providing limited evidence. In fact a 
large observational study of 136 IBM patients showed that 
immunosuppressant drug therapy may modestly exacerbate 
the progression of disability.23 The lack of an adequate 
sample size, a slow and unpredictable progression rate, 
the need for long (and expensive) trial durations, and the 
absence of validated measures of strength limit past and 
future IBM clinical trials. Moreover, IBM is often diagnosed 
years after the onset of symptoms, when muscle damage is 
established and advanced, thus limiting the capability of 
quantifying any treatment response. Therefore, the treatment 
approach is largely empiric, varying considerably between 
centers.25 It has been estimated that in order to demonstrate 
a significant effect from an efficacious treatment for IBM 
in a placebo-controlled study, 200 subjects would need to 
be enrolled in a 6-month study or 100 in a year-long trial.26 
Reports in the literature have included patients lacking classic 
clinical features of IBM (for example very high serum CK 
levels), who may have been misdiagnosed based on biopsy 
criteria alone.13 Only a subgroup of patients with IBM in 
overlap with an autoimmune disorder, occurring in about 
15% of cases,27 appeared to benefit from immunosuppres-
sive treatment.28,29
Corticosteroids
Although corticosteroids are “unproven” in PM and DM, they 
are the first-line treatment in these idiopathic inflammatory 
myopathy (IIM) subsets. Conversely, patients with IBM do 
not consistently improve with corticosteroid treatment, and 
there have been no randomized or even nonrandomized 
studies to evaluate their efficacy in IBM. A small but very 
interesting and informative study by Barohn et al treated 
eight IBM patients with oral prednisone therapy (100 mg 
a day for a month, then 100 mg alternate-day for 6 months), 
and performed pre- and posttreatment muscle biopsies. 
Although the serum CK level fell and inflammation (number 
of nonnecrotic muscle fibers with mononuclear cell invasion) 
decreased in the muscle biopsy specimens, muscle strength 
worsened and the number of vacuolated and amyloid-positive 
fibers increased after prednisone. These observations support 
the notion that a degenerative or fibrotic process may be the 
primary pathogenesis9 and the inflammatory response in 
IBM is secondary. A limitation of this study was its small 
sample size and lack of an untreated “natural history” IBM 
control group, which may have highlighted either a benefit 
or deterioration with steroids. Over a period of 2 years, Lotz 
et al reported that muscle strength continued to deteriorate in 
25 IBM patients treated with prednisone at doses frequently 
effective in PM.27 Joffe et al also noted a poor response to 
prednisone in patients with IBM.30 Conversely, some reports 
have noted a partial response to corticosteroids or stabilization 
of muscle strength,31–33 and Leff et al retrospectively reported 
modest clinical benefit with prednisone in 10 of 25 patients 
with IBM (40%).33 Serum CK levels may fall and even nor-
malize after corticosteroids, but this biochemical response 
did not predict clinical benefit.33 The authors optimistically 
reported that stabilization of an otherwise deteriorating 
course may be an attainable goal using immunosuppressive 
agents in some patients with IBM, however this view is not 
shared by many myositis experts. There is one exception 
to the usually limited response to corticosteroids. Patients 
with IBM coexistent with other connective tissue diseases 
(Sjögren’s syndrome, systemic lupus erythematosus, and 
DM rash) may benefit from steroid therapy, but it remains 
uncertain whether IBM features improve.28,34,35
Oral immunosuppressive agents
Methotrexate and azathioprine
In a randomized double-blind placebo-controlled 48-week 
study, Badrising et al investigated the efficacy of oral 
methotrexate (MTX, mean 14 mg/week) to mitigate disease 
progression in 44 patients with IBM (42 definite IBM, 
2 probable).36 Despite significant decreases in CK levels in 
the MTX group, the primary outcome of quantitative muscle 
strength testing by myometry was not significantly different 
and, in fact, declined in both the treatment groups (−0.2% 
for methotrexate and −3.4% for placebo). There were also 
no differences in manual muscle testing scores, activity scale 
scores and patient-reported outcomes. Post hoc analysis 
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showed that the study was underpowered (23%) to show any 
differences, due to lower than expected decline in muscle 
strength in the placebo group (3.4% instead of 5%), a greater 
than anticipated variability in muscle testing and a greater 
than expected dropout rate from MTX side effects (8/21). 
Joffe et al showed a similar poor response rate to both MTX 
and azathioprine.30
An open-label, randomized crossover trial of combination 
oral azathioprine (AZA) and methotrexate (AZA + MTX) 
and biweekly intravenous (IV) methotrexate with leucovorin 
rescue (IV-MTX-L) was conducted on 11 biopsy-proven IBM 
patients.33 All patients were refractory to previous therapy 
(prednisone with AZA and/or MTX in most patients) with 
active inflammatory muscle disease. Each patient received 
one regimen and then crossed over to the other regimen for the 
same length of time and prednisone was tapered after 1 month 
using a standard regimen. Nineteen of the 22 6-month regi-
mens were completed (9/11 AZA/MTX, 10/11 IV-MTX-L). 
Two patients in the AZA/MTX arm improved and four sta-
bilized, while one improved and seven stabilized in the IV-
MTX-L arm. No improvements were major and no complete 
clinical responses with normalization of muscle strength were 
noted. More than half the patients had a complete laboratory 
(CK) response, but CK normalization again did not predict 
clinical response. All three patients with clinical improvement 
had CK levels . 1000 at baseline and greater inflammation 
on muscle biopsy. The limitations of this study include no 
untreated or placebo group, an inability to measure changes in 
distal muscle weakness, a short observation period of 1 year, 
and a carry-over effect of any crossover trial design.
A retrospective study of 25 IBM biopsy-proven patients 
by the same group showed similar results with 40%, 20%, 
and 25% of patients reporting benefits with prednisone, 
azathioprine, and methotrexate respectively, but none 
achieved complete remission.33 Laboratory responses were 
more impressive with most patients normalizing or improv-
ing their muscle enzymes. The main criticism of this study 
was improvement solely defined by physician judgment, 
which was perhaps biased by observing CK improvement. 
No other clinical features including medication, age, race, 
delay in diagnosis, antinuclear antibody levels, or extracted 
nuclear antigen, predicted improvement or stabilization, 
and the authors concluded that aggressive immunosuppres-
sion might have modest benefit (ie, stabilization of muscle 
weakness) in up to 50% of IBM patients.
Sayers et al reported that 15 of 32 biopsy-proven IBM 
patients showed improvement (n = 3) or delayed progression 
(n = 2) after immune suppression (5 MTX/prednisone), 
whereas all untreated patients clinically deteriorated.31 
In another case series, immunosuppressive treatment in 
16 IBM patients failed to prevent disease progression in all 
but one patient with associated Sjögren’s syndrome.34
To summarize, while clinical improvement with immu-
nosuppressive therapy is rare, there is some evidence to 
suggest that methotrexate and prednisone may lead to disease 
stabilization and/or modest improvement in some patients.
Mycophenolate mofetil
There is a single case report in a patient with biopsy-proven 
IBM and 5 years of progressive weakness responding to 
prednisone and mycophenolate with signs of deterioration 
within 3 months of discontinuing therapy.37
T-cell mediated therapies
Autoaggressive T cells may play a role in the pathogenesis 
of IBM.38 Moreover, data have shown that there is identical 
clonal restriction of TCR expression in muscle-infiltrating 
T-cell lymphocytes in IBM, and these clones persist for many 
years, substantiating their role in a continuous, antigen-driven 
inflammatory reaction.39 Thus, agents targeting T cell activa-
tion and proliferation (calcineurin inhibitors and anti-T-cell 
globulins) have been studied in conjunction with corticos-
teroids by some investigators.
A 2007study reported three patients with “biopsy-proven” 
IBM who responded to cyclosporine or tacrolimus;40 but none 
of the patients had finger flexor, wrist flexor, or quadriceps 
atrophy or weakness, thus failing to meet research criteria for 
even possible or probable IBM.13,21 Three IBM patients were 
treated with either cyclosporin-A or tacrolimus leading to a 
complete or major clinical response in muscle strength after 
3–6 months.40 Steroids were tapered or stopped while the 
clinical response was maintained after a follow-up of 2 years 
suggesting that calcineurin inhibitors might be helpful in 
IBM patients with short duration, high-activity disease with 
autoimmune manifestations. These patients were not typical 
of IBM as all were female and they had primarily proximal 
weakness, limited fibrosis and atrophy with no rimmed 
vacuoles, and high CK levels (∼4000 in 2 of 3 patients). 
The authors countered that these patients had early stage 
disease (1–3 years), higher disease activity, and associated 
autoimmune features (in 2 of 3 thyroiditis). Although it may 
be difficult to discriminate between the efficacy of either 
high-dose steroids or calcineurin inhibitors, or both, an 
increase in calcineurin inhibition without reinduction with 
steroids was initiated and all patients improved. Calcineurin 
inhibitors should be further investigated based on these 
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favorable preliminary results, as well as data supporting 
T-cell targeting in IBM.39,41 Given that lymphocyte infiltrates 
in IBM muscle tissue are CD8+ T cells, targeting these cells 
may represent a valid approach.
An open-label randomized controlled trial in 11 IBM 
patients compared a suboptimal dose of oral methotrexate 
(MTX 7.5 mg/week) versus a combination of MTX preceded 
by 7 days of intravenous anti-T-lymphocyte immunoglobulin 
treatment (ATG-MTX group). At 12 months, the CK 
improved and myometry showed that patients in the ATG-
MTX group (n = 6) increased their mean muscle strength 
by 1.4% compared with an 11.1% decline in MTX group 
(n = 5) (P , 0.021).41 Loss of muscle strength in the 
MTX group was commensurate with the expected average 
disease progression in IBM.42 No ATG-treated patients 
had serum sickness. The beneficial treatment outcome in 
the ATG group was mainly confined to distal muscles of 
upper extremities: handgrip and wrist dorsal extension. 
Following ATG treatment, there is a need for subsequent 
immunosuppressive treatment in order to prevent rapid 
restoration of T-cell repertoire, and for this reason MTX 
was used as baseline therapy.
Finally, a case report of a patient with a severe IBM 
complicated with interstitial pneumonia showed a positive 
response to an aggressive immunosuppressive regimen 
including corticosteroids, cyclophosphamide, and intrave-
nous immunoglobulin (IVIG).43
Intravenous immunoglobulin
The effectiveness of IVIG has been evaluated in two small open 
series and three double-blind studies, but no clear consensus of 
efficacy has been established due to the short duration of the tri-
als and the slow progression of IBM. Although improvement in 
muscle strength and function was noted in three of four IVIG-
treated IBM patients with an effect sustained for 2–4 months,44 
these results were not replicated in subsequent, larger series. 
In an open-label, 3-month uncontrolled study of nine IBM 
patients treated with IVIG, there was no objective muscle 
strength or functional improvement observed although there 
was also no worsening of strength or disability.45  Following 
these small uncontrolled studies, a placebo-controlled ran-
domized double-blind controlled crossover study of 22 IBM 
steroid-refractory patients was conducted to study the efficacy 
and safety of IVIG.46 Patients were randomized to monthly 
infusions of IVIG (2 g/kg) or placebo for 6 months each, 
followed by crossover to the alternative treatment. Overall 
there was no disease progression (ie, stabilization or improve-
ment was recorded) in 90% of patients over 12 months, unlike 
that which might have been expected in untreated patients. 
Moreover, there was a slight overall improvement of 4.9% in 
muscle strength for both groups after 1 year, which contrasts 
with the historical decline of 1.4% per month reported for 
untreated IBM patients.9,42 A mild and significant improve-
ment (11%) in clinical symptoms was noted in the IVIG 
group using neuromuscular symptom scores, but only a trend 
toward improvement was found using a modified Medical 
Research Council (MRC) scale. There was no difference in 
response to treatment with respect to CK levels or inflamma-
tory changes on muscle biopsy specimens, but an improvement 
trend with IVIG was observed in patients with baseline CK 
levels . 500 U/L. Further efficacy of IVIG was supported by 
follow-up of 10 patients on IVIG and three patients off IVIG, 
where a trend towards slower decline in muscle strength was 
observed with IVIG after a mean follow up of 15.7 months 
(5.6–24.3 months). Thus, IVIG may be slightly effective in 
IBM by preventing disease progression. However, it remains 
unclear as to what extent the overall improvement can be 
attributed to specific immunomodulatory actions of IVIG 
or to nonspecific effects brought about by the general care 
of patients including physiotherapy. Similar findings have 
been reported by Dalakas et al in a randomized crossover, 
double-blind placebo-controlled study over 6 months of 
19 IBM patients each treated with 3 months of monthly IVIG 
and placebo.47 In this study, six patients showed functionally 
important improvement (.10 MRC points) that declined 
when crossed over to placebo. Although dysphagia improved 
significantly, only small trends of improvement or stabiliza-
tion were noted with IVIG, and the study failed to achieve its 
primary end point.
Supporting the hypothesis of IBM as an immune-mediated 
process is the stabilization of disease after discontinuation 
of IVIG treatment (through 6 months of a placebo phase).48 
T-cell mediated cytotoxity along with further invasion of 
nonnecrotic muscle fibers may be downregulated by IVIG, as 
shown by histological examination of muscles before and after 
treatment.49 The possible synergistic effect of prednisone with 
IVIG led to another double-blind randomized controlled trial in 
36 patients with biopsy-proven IBM. Patients were randomized 
to receive IVIG or placebo monthly for 3 months; before 
infusions, all patients also received high dose prednisone 
for 3 months. When compared to baseline, there were no 
significant differences in muscle strength during 4 months of 
observation. Follow-up biopsies in 24 random patients revealed 
a greater reduction in the number of necrotic myofibers and 
endomysial inflammation in IVIG-treated patients, but this did 
not translate into clinical improvement.46
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The effectiveness of IVIG in IBM-associated dysphagia 
has been reported, and in one report, four patients with severe 
dysphagia due to upper esophageal dysfunction all recovered 
swallowing function after treatment with 6 to 8 monthly 
infusions of IVIG.50 This observation is consistent with the 
efficacy of IVIG seen in life-threatening steroid-resistant 
esophageal involvement in PM/DM patients.51 In patients 
refractory to IVIG cricopharyngeal myotomy seems to be 
the most beneficial interventional measure.52–54 Other inter-
ventions including botulinum toxin injection into the upper 
esophageal sphincter and upper esophageal dilatation have 
been used with variable results.6,52–55
The lack of definitive improvement in muscle strength in 
these IVIG trials is disappointing, and the therapeutic dilemma 
in IBM continues. Whether only certain immunopathologic 
changes responsible for muscle fiber injury are amenable 
to IVIG therapy is unclear. Since IBM begins insidiously, 
and the duration of the disease in a given muscle is difficult 
to assess objectively, the longer the duration of the disease 
and the greater the degree of vacuolization or replacement 
of muscle fibers by fibrous tissue, the more resistant these 
muscles may be to immunotherapies. IVIG, by inhibiting 
cytokines or blocking Fc receptors on macrophages, 
may only affect muscle groups with intense endomysial 
inflammation and not muscles with progressive vacuolization 
and fibrosis. Future long-term studies aimed at slowing down 
disease progression rather than improving strength may be 
more realistic in such a chronic, slow, progressive disease. 
Contributing to this therapeutic dilemma is the prohibitive 
expense and occasional scarcity of this drug, along with 
the potential for side effects such as infusion reactions and 
hypercoagulability. Does the moderate global benefit noted 
in a few patients and the mild benefit in certain muscle 
groups noted in others justify the use of IVIG in this disease? 
The present findings do not provide an answer but suggest 
that a large controlled study may be warranted.
Biological agents
Biologic agents targeting presumptive immunopathological 
processes such as B and T cell-mediated muscle inflamma-
tion and/or damage have been studied in IBM patients with 
variable results.
Interferon therapy
β-Interferon (β-IFN), an immunomodulatory cytokine, is 
known to counteract the immune-stimulatory effects of 
alpha-interferon (IFNα), such as the activation of cytotoxic 
T lymphocytes, secretion of lymphokines, and upregulation 
of HLA on many cell surfaces. Moreover, β-IFN inhibits 
lymphocyte migration across endothelial cell surfaces by 
decreasing T-cell production of matrix metalloproteinase-9 
and other chemotactic chemokines that may play a role in the 
pathogenesis of IBM. Given that the inflammatory infiltrates 
in IBM include cytotoxic T cells and macrophages, β-IFN was 
studied as a candidate therapeutic agent for IBM. A 6-month 
multicenter, randomized, placebo-controlled pilot trial of 
interferon-beta-1a (30 µg intramuscularly [IM]/week) in a 
group of 30 patients with IBM demonstrated no improvement 
in muscle strength or mass.56 A subsequent similarly designed 
trial using a higher dose (60 µg IM injection/week) in 
30 subjects was also ineffective even though both trials met the 
primary outcome of safety and tolerability of β-IFN in IBM.57 
A case report noted IBM developing after IFNγ treatment 
for hepatitis C followed by relapse of IBM after reinitiation 
of IFNγ.58 A second case report of a Japanese IBM patient 
who was a carrier of hepatitis C, showed significant clinical 
improvement in muscle weakness with β-IFN treatment.59
Alemtuzumab (CAMPATH)
Alemtuzumab (Campath, Campath-1H, or MabCAMPATH), 
approved for the treatment of T cell leukemia, is a humanized 
T-cell-depleting monoclonal antibody against CD52 that 
causes profound T cell depletion in the periphery and lym-
phoid tissues.60 Based on its efficacy in multiple sclerosis,61 
Dalakas et al studied CAMPATH in IBM and demonstrated 
a long-lasting drop in peripheral T cells resulting in a reduc-
tion of endomysial T cells.62 Thirteen patients were treated 
with alemtuzumab (0.3 mg/kg/day for 4 days) and primary 
end-points were disease stabilization or increased strength 
6 months after treatment as compared to natural history 
data 12 months prior to therapy. Alemtuzumab significantly 
slowed disease progression during the 6 months treatment 
phase (11.4% improvement in manual muscle testing [MMT] 
over 6 months versus 13.8% worsening in the 12 month pre-
treatment phase), improving the strength of some patients, 
and reducing the inflammation and degeneration-associated 
molecules. The lack of blinding and placebo control makes 
accurate assessment difficult. Larger, blinded placebo-
controlled trials with multiple infusions to assess the long-
term efficacy and safety (especially important given safety 
concerns in recent MS trials) are warranted.61
Antitumor necrosis factor agents
The production of proinflammatory cytokines, including 
tumor necrosis factor-α (TNF-α), is increased in muscle 
tissue from patients with IBM as compared to normal 





Degenerative Neurological and Neuromuscular Disease 2012:2
controls, indicating a potential role of TNF in the genesis of 
IBM.63,64 Etanercept, a TNF receptor fusion protein that binds 
and inactivates TNF, has proven safety and effectiveness 
in autoimmune diseases, particularly rheumatoid arthritis. 
A pilot trial of nine IBM patients treated with etanercept 
(25 mg SQ twice weekly) noted no improvement in com-
posite muscle strength scores at 6 months, although there 
was a slight improvement in grip strength after 12 months 
of treatment, as compared to natural history control data.65 
Similar results with infliximab (another anti-TNF agent) 
were seen when refractory myositis patients, including four 
with IBM, were treated in a 4-month, open-label uncon-
trolled trial.66 One of four IBM patients had a composite 
clinical response, three remained unchanged, and none 
worsened after four infliximab infusions over 14 weeks. 
No significant improvement was observed in muscle tis-
sue, muscle strength by MMT or muscle enzyme levels. 
Interestingly, some authors have also reported IBM after 
anti-TNF agents.66–69
Rituximab
Although B-cell-mediated inflammation was suggested 
to contribute to the pathogenesis of IBM,70 the reports of 
B-cell depletion therapy with rituximab in IBM are limited 
to a few case reports without favorable outcome.71 In a case 
report of IBM and rheumatoid arthritis (RA), treated with 
rituximab for active arthritis, no amelioration of muscle 
weakness was noted.69 Given some encouraging results on 




Testosterone increases muscle bulk and strength when 
combined with exercise in normal males,72 and has shown 
modest effects in improving strength in boys with Duchenne 
muscular dystrophy.73,74 Oxandrolone (a synthetic androgen) 
showed a trend towards improvement in whole-body strength 
and a significant effect in improving upper-extremity strength 
in an 8-month double-blind, crossover trial of 19 IBM 
patients. The authors concluded that given some favorable 
results further study of this drug in combination with an 
immunomodulatory agent is warranted.75
Empiric therapies
Despite the lack of controlled clinical trials, clenbuterol 
(a β
2
 agonist), coenzyme Q10 (ubiquinone), carnitine, and 
antioxidants have been recommended by some experts.76
Exercise therapy
Randomized, controlled studies of exercise training in active 
PM and DM have demonstrated a beneficial response and 
the absence of adverse effects on the disease process.76–79 
Studies in IBM also showed no worsening of muscle 
function, histopathology and inflammation and muscle 
enzyme levels after an exercise program.80 Furthermore, 
aerobic and strength training in IBM patients was safe and 
can lead to dynamic strength improvements, and (possibly) 
prevent continued loss of muscle strength.81 A more recent 
well-designed unblinded, uncontrolled study has shown 
that a closely monitored, 16-week, home-based program of 
strength and flexibility training can lead to significant gains 
in muscle strength and function in patients with IBM.82 The 
protocol was well tolerated by all the patients and did not 
cause adverse muscle symptoms or elevation of serum CK 
levels. The authors further demonstrated that the addition 
of an aerobic exercise program was well tolerated in IBM 
patients and improved aerobic capacity and muscle strength 
when combined with resistance training.82
Conclusion
IBM is a complex, disabling disease, which is notoriously 
resistant to therapies. It is often suspected, retrospectively, 
when patients diagnosed with PM have failed treatment with 
standard immunosuppressive medications. Understanding 
the interplay between inflammation and degeneration and 
elucidating the mechanisms that drive muscle degeneration 
on a cellular basis is a crucial step in identifying potential 
therapeutic targets. Moreover, identification of susceptibility 
genes will be important to unravel its pathogenesis, and 
to provide clues to the development of targeted therapies. 
Due to the significant delay in diagnosis of IBM, striated 
muscle has undergone considerable damage and has already 
been replaced by fat or fibrosis by the time the condition is 
diagnosed. Therapies directed solely at decreasing inflam-
mation cannot be expected to reverse weakness from atrophy 
and fibrosis.
Unfortunately, no comparative patient cohorts have the 
requisite follow-up to determine the long-term outcome 
after introduction of immunosuppressive agents. Thus, the 
more practical and achievable goal for the treatment of IBM 
with immunosuppressive agents is slowing the progression 
of muscle fiber destruction. There is an urgent need for 
IBM trials of adequate duration, sufficient power and the 
inclusion of patients with early disease. Currently, the 
balance of evidence suggests that immunosuppressive drugs 
including corticosteroids are ineffective in IBM, although 
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long-term randomized controlled trials are lacking. IVIG 
is a reasonable consideration in IBM with some suggestion 
of slowing the progression of the disease, but its long-
term effectiveness remains unknown. Whether the modest 
gains noted in some IBM patients justify the high cost of 
IVIG remains unclear. Biological therapies, especially 
alemtuzumab, show some promise, but confirmation is 
necessary before these drugs are accepted for use in IBM. 
Moreover, drugs like follistatin that inhibit myostatin, a 
member of the transforming growth factor-β family of 
secreted growth factors and a potent suppressor of muscle 
growth that is being tested in muscle dystrophy, need to 
be studied as potential therapeutic targets in IBM. Other 
novel therapies like stem cell transplantation and autophagy 
pathways need to be explored in IBM due to the lack of 
efficacy of immunosuppressive therapies.83
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